Pain Therapeutics Inc (PTIE)

4.15
NASDAQ : Health Care
Prev Close 4.07
Day Low/High 4.00 / 4.20
52 Wk Low/High 3.10 / 20.86
Avg Volume 35.20K
Exchange NASDAQ
Shares Outstanding 6.60M
Market Cap 26.84M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pain Therapeutics Announces FDA Has Cleared An Investigational New Drug (IND) Application For PTI-125

Pain Therapeutics Announces FDA Has Cleared An Investigational New Drug (IND) Application For PTI-125

Clinical Study Initiation Is Expected Shortly, with Funding by NIH

NIH Awards $1.7 Million Research Grant To Pain Therapeutics To Study Alzheimer's Disease

NIH Grant Will Support Clinical Testing of PTI-125, an Experimental Drug Candidate

Pain Therapeutics Announces Research Publication On Alzheimer's Disease

PTI-125, an Experimental Drug, Restored Receptor Function and Significantly Improved Working Memory and Spatial Ability in a Transgenic Mouse Model of Alzheimer's Disease

Pain Therapeutics Announces Reverse Stock Split

Stock to Trade on a Split-adjusted Basis Beginning May 10, 2017

Pain Therapeutics Announces Positive Regulatory Guidance For REMOXY™ ER

- Company Will Host Conference Call on Tuesday, March 21st, at 8am Eastern Time -

Pain Therapeutics To Discuss REMOXY® ER With FDA

Pain Therapeutics To Discuss REMOXY® ER With FDA

FDA Meeting Set for February 13, 2017

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

Here's a technical look at how to trade some of the most active stocks on the market right now.

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Failure is very profitable for Pain Therapeutics CEO Remi Barbier.

Putting 2 Biotechs Under the Microscope

These low-dollar biotech stocks are making big moves Monday -- in opposite directions.

Complete Response Letter For REMOXY®

Complete Response Letter For REMOXY®

Company Will Host Conference Call Monday, September 26th at 9:00am EDT

Pain Therapeutics Announces Advisory Committee Meeting For REMOXY® Is Not Needed

Pain Therapeutics Announces Advisory Committee Meeting For REMOXY® Is Not Needed

No Change to September 25th PDUFA Date

Pain Therapeutics Reports 2015 Financial Results And Corporate Update

Pain Therapeutics Reports 2015 Financial Results And Corporate Update

Focus in 2016 Will be on REMOXY, Fiscal Discipline and Advancing Pipeline

Pain Therapeutics Reports Q3 2015 Financial Results And Update On REMOXY

Pain Therapeutics Reports Q3 2015 Financial Results And Update On REMOXY

Focus Remains on NDA Resubmission to FDA, Targeted for Q1 2016

Short Interest In Pain Therapeutics Makes 27.2% Move

Short Interest In Pain Therapeutics Makes 27.2% Move

The most recent short interest data has been released by the NASDAQ for the 05/29/2015 settlement date, which shows a 650,044 share increase in total short interest for Pain Therapeutics Inc , to 3,037,711, an increase of 27.23% since 05/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Pain Therapeutics Announces Update On Drug Portfolio

Pain Therapeutics Announces Update On Drug Portfolio

Conference Call Tomorrow, Tuesday, at 4:30 p.m. Eastern Time